Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy

Autor:	Makoto Nakamura, Tomohiro Urata, Yasuhisa Sando, Nobuharu Fujii, Kyosuke Saeki, Yuichi Sumii, Yoshinobu Maeda, Hisakazu Nishimori, Keiko Fujii, Yuki Fujiwara, Masaya Abe, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Kentaro Mizuhara, Ken-ichi Matsuoka, Michinori Aoe, Keisuke Seike, Takahide Takahashi
Rok vydání:	2019
Předmět:	medicine.medical_specialty Adolescent medicine.medical_treatment B-Lymphocyte Subsets Hematopoietic stem cell transplantation Post-transplant lymphoproliferative disorder Hypogammaglobulinemia Postoperative Complications Refractory immune system diseases Agammaglobulinemia hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Adverse effect Cytopenia Hematology business.industry Hematopoietic Stem Cell Transplantation medicine.disease Immunoglobulin Class Switching Lymphoproliferative Disorders surgical procedures operative Immunoglobulin G Immunology Rituximab Female business medicine.drug
Zdroj:	International journal of hematology. 112(3)
ISSN:	1865-3774
Popis:	Post-transplant lymphoproliferative disorder (PTLD) is one of the most serious complications of allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab is effective for PTLD; however, rituximab can produce adverse effects, including hypogammaglobulinemia. Here, we present the case of an 18-year-old female with refractory cytopenia of childhood who developed persistent selective hypogammaglobulinemia with low immunoglobulin G (IgG) 2 and IgG4 levels and monoclonal protein after rituximab therapy against probable PTLD. Despite B-cell recovery, the serum IgG levels gradually declined, reaching
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18da829546665b9396d7e7250e324556 https://pubmed.ncbi.nlm.nih.gov/32342335 Zobrazit plný text záznamu Full text from SpringerLink